New Data Suggesting Positive Effects of Sanofi Genzyme’s Lemtrada (Alemtuzumab) On Brain Volume Loss And Retinal Nerve Fibers To Be Presented At American Academy of Neurology

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sanofi Genzyme, the specialty care global business unit of Sanofi, today announced that positive new brain volume data from an ongoing clinical study of Lemtrada® (alemtuzumab) will be presented at the 68th American Academy of Neurology (AAN) Annual Meeting. In addition, new data from an exploratory study will be presented which demonstrate the impact of Lemtrada on retinal nerve fibers.